Chronic obstructive pulmonary disease (COPD)
Drug research and approvals for chronic obstructive pulmonary disease (COPD): what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 21, 2026, 437 studies of chronic obstructive pulmonary disease (COPD) are recruiting on ClinicalTrials.gov, Health Canada has authorized 89 drug trials for it since 2013, FDA has 0 approved and 2 open orphan designations naming it, and the EU has 19 authorised medicines for it.
- Recruiting worldwide: 437
- Trials authorized in Canada: 89
- FDA orphan approvals: 0
- EU medicines: 19
- Automated Oxygen Titration With the EMILY.AI Device During the Six-Minute Walk TestNCT07938086 · Not applicable · Aether Tech S.L. · starts Apr 15, 2026
- Cardiopulmonary Exercise Active Health Cohort StudyNCT07935187 · Not reported · Peking University Third Hospital · starts May 11, 2026
- Chronic Respiratory Disease Participant Engagement StudyNCT07924462 · Not reported · Richmond Research Institute · starts Nov 1, 2026
- A Study to Assess the Efficacy and Safety of Co-administration of GSK3862995B With GSK5784283 in Adult Participants…NCT07915791 · Phase 2 · GlaxoSmithKline · starts Oct 29, 2026
- Reducing Exposure With Air Cleaners and TechnologyNCT07914010 · Not applicable · University of California, Berkeley · starts Nov 17, 2026
- A Study to Investigate the Efficacy and Safety of Zelicapavir Compared With Placebo in Adults With RSV Who Are at High…NCT07908381 · Phase 2 / Phase 3 · Enanta Pharmaceuticals, Inc · starts Oct 19, 2026
- Construction and Validation of an Impulse Oscillometry (IOS)-Based Platform for Screening, Diagnosis, and Management of…NCT07910409 · Not reported · Beijing Chao Yang Hospital · starts Apr 1, 2026
- Multimodal Assessment of Neuromuscular Electrical Stimulation (NMES) Effects on Respiratory and Peripheral Muscles in…NCT07910006 · Not applicable · Universitas Padjadjaran · starts Nov 1, 2026
- Phase 2b Efficacy and Safety Study of AERO-007, an Inhaled LABA+LAMA Combination for Nebulization Delivery in COPD…NCT07896252 · Phase 2 · AeroRx Therapeutics Inc. · starts Nov 1, 2026
Approved 20
- TiotropiumMuscarinic acetylcholine receptor M3 antagonist
- Fluticasone propionateGlucocorticoid receptor agonist
- GlycopyrroniumMuscarinic acetylcholine receptor M3 antagonist
- SalmeterolBeta-2 adrenergic receptor agonist
- FormoterolBeta-2 adrenergic receptor agonist
- BudesonideGlucocorticoid receptor agonist
- VilanterolBeta-2 adrenergic receptor agonist
- AlbuterolBeta-2 adrenergic receptor agonist
- Fluticasone furoateGlucocorticoid receptor agonist
- OlodaterolBeta-2 adrenergic receptor agonist
- UmeclidiniumMuscarinic acetylcholine receptor M3 antagonist
- RoflumilastPhosphodiesterase 4 inhibitor
- IndacaterolBeta-2 adrenergic receptor agonist
- AclidiniumMuscarinic acetylcholine receptor M3 antagonist
- IpratropiumMuscarinic acetylcholine receptor M3 antagonist
- RevefenacinMuscarinic acetylcholine receptor M3 antagonist
- AzithromycinBacterial 70S ribosome inhibitor
- EnsifentrinePhosphodiesterase 4 inhibitor
- ArformoterolBeta-2 adrenergic receptor agonist
- Prednisolone phosphoric acidGlucocorticoid receptor agonist
Phase 3 12 of 50
- Beclomethasone dipropionateGlucocorticoid receptor agonist
- MoxifloxacinTopoisomerase IV inhibitor
- TheophyllinePhosphodiesterase 4 inhibitor
- MepolizumabInterleukin-5 inhibitor
- ItepekimabInterleukin-33 inhibitor
- Fluticasone
- BenralizumabInterleukin-5 receptor subunit alpha inhibitor
- Ivospemin
- CiprofloxacinBacterial DNA gyrase inhibitor
- PrednisoneGlucocorticoid receptor agonist
- SimvastatinHMG-CoA reductase inhibitor
- LevofloxacinDNA gyrase inhibitor
Phase 2 12 of 96
- BatefenterolBeta-2 adrenergic receptor agonist
- DarotropiumMuscarinic acetylcholine receptor antagonist
- DanirixinInterleukin-8 receptor B antagonist
- TranimilastPhosphodiesterase 4 inhibitor
- NemiralisibPI3-kinase p110-delta subunit inhibitor
- LosmapimodMAP kinase p38 alpha inhibitor
- AlvelestatLeukocyte elastase inhibitor
- CholecalciferolVitamin D receptor agonist
- PH-797804MAP kinase p38 alpha inhibitor
- CarmoterolBeta-2 adrenergic receptor agonist
- IvacaftorCystic fibrosis transmembrane conductance regulator positive modulator
- NivolumabProgrammed cell death protein 1 inhibitor
Phase 1 or earlier 12 of 45
- GSK2256294Epoxide hydratase inhibitor
- Charcoal, activated
- CyclosporineCyclophilin A modulator
- ItraconazoleCytochrome P450 51 inhibitor
- KetoconazoleCytochrome P450 51 inhibitor
- PropranololBeta-1 adrenergic receptor antagonist
- OmeprazolePotassium-transporting ATPase inhibitor
- Nitric oxideSoluble guanylate cyclase activator
- ElubrixinInterleukin-8 receptor B antagonist
- BedoradrineBeta-2 adrenergic receptor agonist
- XenonDiagnostic agent
- Magnesium stearate
How its trials ended
3,551 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrongOf the 913 whose ending is known, 59% met their primary endpoint, 10% missed it and 32% stopped early.
- Completed, result not reported1,68047%
- Met its primary endpoint53715%
- Status unknown49014%
- Ongoing46813%
- Stopped: other or unclear1715%
- Missed its primary endpoint872%
- Stopped: enrollment or feasibility682%
- Stopped: sponsor or business decision261%
- Stopped: lack of efficacy13<1%
- Stopped: funding10<1%
- Stopped: safety1<1%
| Sep 25, 2026 | Alarmony: a phase 2 randomized, double blind, placebo controlled multicenter study to assess the efficacy and safety of co-administration of GSK3862995B with…GSK3862995B / GSK5784283 | GSK | Pending |
| Sep 14, 2026 | Airway dysfunction, occlusions and remodeling: COPD patients and mepolizumabHyperpolarized XENON-129 | Robarts Research Institute, Western University | Pending |
| Sep 3, 2026 | A randomized, double-blind, placebo-controlled study comparing the efficacy of dupilumab added on to standard of care (SOC) treatment vs soc treatment…Dupixent | Regeneron | Pending |
| Jul 29, 2026 | An extension study to evaluate the long-term safety and efficacy of lunsekimig including inhaled corticosteroid withdrawal, in adults with chronic obstructive…Lunsekimig (SAR443765) | Sanofi-Aventis Canada Inc | Ongoing |
| Jun 30, 2026 | A randomized, double-blind, placebo-controlled, parallel arm, 52-week study to assess efficacy, safety, tolerability, and pharmacokinetics of two doses of…EXPD-101 | Expedition Therapeutics Inc. | Ongoing |
| Jun 16, 2026 | A phase 2, multicenter, randomized, double-blind, 52-week study to investigate the efficacy and safety of brenipatide compared with placebo for the treatment…Brenipatide (LY3537031) | Eli Lilly | Pending |
| Dec 24, 2025 | An interventional phase 2/3 randomized, double-blind, third party-unblinded, placebo-controlled parallel-group study to investigate efficacy and safety of…PF-07275315 | Pfizer | Ongoing |
| Dec 11, 2025 | A multicenter, randomized, double-blind, parallel group, placebo-controlled study of the efficacy and safety of early depemokimab initiation as add-on…Depemokimab (GSK3511294) | GSK | Ongoing |
| Oct 22, 2025 | Mechanistic 129xe MRI study of single inhaler ff/umec/vi effects in COPD patients with persistent, moderate-severe dyspnea and/or poor health status with high…Hyperpolarized xenon (129XE) | Robarts Research Institute, Western University | Ongoing |
| Sep 3, 2025 | Understanding the role of airway mucus occlusions in Canadians with asthma, COPD and chronic cough (CANMUC)Hyperpolarized XENON-129 | McMaster University | Pending |
| Nov 2, 2004 | Sitaxsentan SodiumFor the treatment of pulmonary arterial hypertension in the absence of chronic obstructive pulmonary disease or congestive heart failure. | Pfizer Global Research and Development | Designated |
| Aug 28, 2001 | Recombinant human alpha-1 antitrypsin (rAAT)To delay progression of chronic obstructive pulmonary disease resulting from AAT deficiency-mediated emphysema and bronchiectasis | AiroMedica LLC | Designated |
| Dec 18, 2018 | Bevespi AerosphereGlycopyrronium; formoterol fumarate dihydrate | AstraZeneca AB | EMA ↗ |
| Apr 26, 2018 | TrydonisBeclometasone; formoterol; glycopyrronium bromide | Chiesi Farmaceutici S.p.A. | EMA ↗ |
| Nov 15, 2017 | Elebrato ElliptaFluticasone furoate; umeclidinium; vilanterol | GlaxoSmithKline Trading Services Limited | EMA ↗ |
| Nov 15, 2017 | Trelegy ElliptaFluticasone furoate; umeclidinium; vilanterol | GlaxoSmithKline Trading Services Limited | EMA ↗ |
| Mar 20, 2017 | Rolufta Ellipta (previously Rolufta)Umeclidinium | GlaxoSmithKline Trading Services Limited | EMA ↗ |
| Nov 19, 2014 | Brimica GenuairAclidinium; formoterol fumarate dihydrate | Azurity Pharmaceuticals Ireland Ltd. | EMA ↗ |
| Nov 19, 2014 | Duaklir GenuairAclidinium bromide; formoterol | Azurity Pharmaceuticals Ireland Ltd. | EMA ↗ |
| May 8, 2014 | Laventair Ellipta (previously Laventair)Umeclidinium bromide; vilanterol | GlaxoSmithKline Trading Services Limited | EMA ↗ |
| May 8, 2014 | Anoro Ellipta (previously Anoro)Umeclidinium bromide; vilanterol | GlaxoSmithKline Trading Services Limited | EMA ↗ |
| Apr 28, 2014 | Incruse Ellipta (previously Incruse)Umeclidinium bromide | GlaxoSmithKline Trading Services Limited | EMA ↗ |
| Apr 23, 2014 | Ulunar BreezhalerIndacaterol; glycopyrronium bromide | Novartis Europharm Limited | EMA ↗ |
| Sep 19, 2013 | Ultibro BreezhalerIndacaterol; glycopyrronium bromide | Novartis Europharm Limited | EMA ↗ |
| Sep 18, 2013 | Xoterna BreezhalerIndacaterol; glycopyrronium bromide | Novartis Europharm Limited | EMA ↗ |
| Sep 28, 2012 | Tovanor BreezhalerGlycopyrronium bromide | Novartis Europharm Limited | EMA ↗ |
| Sep 28, 2012 | Seebri BreezhalerGlycopyrronium bromide | Novartis Europharm Limited | EMA ↗ |
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA